KR102130332B1 - Health fuctional food composition for preventing or improving liver diseases comprising Gastrodia elata and larva - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of liver disease containing a mixed fermentation product of cheonma and slug as an active ingredient and a composition of a health functional food composition and a method of manufacturing a mixed fermentation product of cheonma and slug for improvement of liver function.

Description

Health fuctional food composition for preventing or improving liver diseases comprising Gastrodia elata and larva}

The present invention relates to a health food composition for the prevention or treatment of liver disease containing cheonma and slug as an active ingredient, the composition of the present invention while rapidly reducing the alcohol in the blood, alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase ( ALDH) activity is increased, blood aspartic acid aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyltranspeptidase (γ-GTP), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) ) As activity decreases, it can be very useful as a health functional food for prevention and improvement of liver disease.

In recent years, the phenomenon of having frequent drinking spots is increasing as a way to relieve stress due to changes in the social structure and work. Due to such frequent drinking, serious problems in human health caused by alcohol have been raised, and research on the development of health functional foods and drugs has been actively conducted. In the case of a representative liver disease that currently used in clinical treatments Sicily blank (silybin), and silymarin (silymarin) has been separated from the fruit of plants in the Asteraceae Mary thistle (Silybum marianum), secondary electron (Plantago Asiatica ), acubin, ursodesoxycholic acid, and vitamin B group are used as treatments for liver toxicity. It can be said that the development of therapeutic agents for liver disease in natural products has great significance.

Gastrodia elata Blume) is a perennial plant belonging to the Orchidaceae family, symbiotic with the mycelium of the mulberry mushroom and possessing tubers in the ground. Cheonma is known to be effective in hypertension, paralysis, headache, neurological diseases, diabetes, epilepsy, and dizziness. Gastrodine, p-hydroxy benzyl alcohol, p-hydroxy benzyl aldehyde, vanillin and the like have been reported as pharmacological components of Cheonma.

The clinical efficacy of Cheonma is included in Shinnongbon Carbide, Scented Herbs, Forest Economy, Donguibogam, and Pharm, etc., mainly clearing blood, removing blood and blood, removing phlegm and moisture, treating wind, cutting inflammation, and essence It is known as an herbal medicine that has various effects such as increasing the amount of blood, stopping the bleeding, stopping diarrhea, releasing poison, neutralizing or alleviating various medicinal properties, and stopping the pain, and is also effective in blood pressure, stroke, headache, and diabetes. have. When analyzing papers on the efficacy of Cheonma, which has been searched since 1994 through Kisti NDSL, the number of papers was found to be about 64. The main efficacy of the papers using Cheonma was mainly the improvement of cerebrovascular disease, and the following were mainly the three main points of view, including experiments related to hypertension and the effect of improving obesity through lipolysis. There were many, and it has been reported about neurostable action, cardiovascular improvement, cholesterol lowering effect, and antioxidant action.

Most of the ingredients contained in Cheonma are phenolic compounds, and gastrodin, phenolic glycosides, sulfur-containing phenolic compounds, organic acids, sugars, and beta-sitosterol have been reported separately. (sterol), cholesterol (cholesterol), p-hydroxybenzyl alcohol (p-hydroxylbenvyl alcohol) and vanillin (vanillin) and other ingredients are known, but the development of products for Cheonma has not been done properly, conventional There was only a medicinal or oriental medicine clinic used for cutting.

In the mid-1990s, artificial cultivation technology was developed and production increased, but in the meantime, its use has been restricted due to restrictions on raw materials that cannot be used as food by the Korea Food and Drug Administration. However, as of September 1, 2000, regulations were lifted and commercialization became possible, and it is necessary to increase the utilization of Cheonma. As mentioned above, Cheonma has very excellent physiologically active ingredients or medicinal properties as a processed product material, but the taste is too strong and the odor is strong, making it difficult to use as a food or pharmaceutical material than other herbal materials in terms of overall preference.

Korean Patent Publication No. 2015-0127808 discloses a pharmaceutical composition for the treatment and prevention of liver disease containing ultra-high pressure treated bean sprout extract, and Korean Registered Patent No. 0762448 discloses a liver disease containing an herbal extract containing an active ingredient as an active ingredient. Although a health food composition for prevention and treatment has been disclosed, it is different from a health food composition for preventing or improving liver disease containing the thousand horses and slugs of the present invention as active ingredients.

The present invention was devised by the above-mentioned needs, and the present inventors confirmed that the mixed fermentation product fermented by adding a lactic acid bacteria culture solution to a mixture of cheonma powder and slug powder increases the effect of preventing or treating liver disease. By doing so, the present invention was completed.

In order to solve the above problems, the present invention provides a pharmaceutical composition for the prevention or treatment of liver disease containing a mixture of cheonma and slugs as an active ingredient.

In addition, the present invention provides a health functional food for the prevention or improvement of liver disease containing a mixture of cheonma and slug as an active ingredient.

In addition, the present invention comprises the steps of (1) preparing sterilized mixture of Cheonma powder and slug powder; And (2) adding water and lactic acid bacteria culture solution to the mixture prepared in the step (1), followed by fermentation, thereby providing a method of manufacturing a mixture of fermented cheonma and slug for liver function improvement.

The cheonma and slug mixed fermentation product of the present invention rapidly decreases alcohol in the blood while increasing the activity of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH), blood aspartic acid aminotransferase (AST), alanine aminotransferase ( ALT), gamma glutamyltranspeptidase (γ-GTP), alkaline phosphatase (ALP) and lactic acid dehydrogenase (LDH) activity are reduced, which is very useful as a health functional food for prevention and improvement of liver disease Can be.

In order to achieve the object of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of liver disease containing a mixture of cheonma and slug as an active ingredient.

In the pharmaceutical composition for preventing or treating liver disease of the present invention, the fermented mixture of cheonma and slug is preferably sterilized by mixing a mixture of cheonma powder and slug powder at a weight ratio of 1 to 2: 1, followed by water. And after adding the lactic acid bacteria culture solution may be prepared by fermentation for 66 to 78 hours in an incubator of 36 ~ 38 ℃, more preferably sterilized mixture of a thousand powder and slug powder in a weight ratio of 1 to 2: 1 Then, after adding water and lactic acid bacteria culture solution to this, it may be prepared by fermenting for 72 hours in a 37°C incubator, but is not limited thereto.

In addition, in the pharmaceutical composition for preventing or treating liver disease of the present invention, the'slugs' may be larvae of white spotted flower radish ( Protaetia brevitarsis ), but are not limited thereto.

In addition, in the pharmaceutical composition for preventing or treating liver disease of the present invention, the liver disease may be fatty liver, alcoholic fatty liver, chronic hepatitis, acute hepatitis, alcoholic hepatitis, cirrhosis or alcoholic cirrhosis, but is not limited thereto.

The composition for preventing or treating liver disease of the present invention may include suitable carriers, excipients, and diluents commonly used in the manufacture of pharmaceutical compositions.

The pharmaceutical dosage form of the composition for preventing or treating liver disease of the present invention can also be used in the form of their pharmaceutically acceptable salts, and can be used alone or in combination with other pharmaceutically active compounds as well as a suitable set. .

The composition for preventing or treating liver disease according to the present invention is an oral dosage form such as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, external preparation, suppository, and sterile injectable solution, respectively, according to a conventional method. It can be formulated in form and used. Carriers, excipients and diluents that can be included in the composition for the prevention or treatment of liver disease include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate , Various compounds or mixtures including calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. have. In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include at least one excipient in the extract, for example, starch, calcium carbonate, sucrose ) Or by mixing lactose, gelatin, and the like. In addition, lubricants such as magnesium stearate and talc are used in addition to simple excipients. Liquid preparations for oral use include suspensions, intravenous solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are common diluents, various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, can be included. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerogelatin may be used.

The preferred dosage of the composition for preventing or treating liver disease of the present invention varies depending on the patient's condition and body weight, the degree of the disease, the drug form, the route and duration of administration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the composition for preventing or treating liver disease of the present invention is preferably administered at 0.0001 to 100 mg/kg per day, preferably at 0.001 to 100 mg/kg per day. Administration may be administered once a day, or may be divided into several times. The above dosage does not limit the scope of the present invention in any way.

The composition for preventing or treating liver disease of the present invention can be administered to various mammals, such as rats, mice, livestock, and humans. Any mode of administration can be expected, for example, oral, rectal, intravenous, intramuscular, subcutaneous, intrathecal epidural or intracerebroventricular injection.

In addition, the present invention provides a health functional food for the prevention or improvement of liver disease containing a mixture of cheonma and slug as an active ingredient.

In the health functional food for preventing or improving liver disease of the present invention, the liver disease may be fatty liver, alcoholic fatty liver, chronic hepatitis, acute hepatitis, alcoholic hepatitis, cirrhosis or alcoholic cirrhosis, but is not limited thereto.

When the mixed fermentation product for prevention or improvement of liver disease of the present invention is used as a food additive, the mixed fermentation product for prevention or improvement of liver disease can be added as it is or used with other food or food ingredients, Depending on the method, it can be suitably used. The amount of the active ingredient to be mixed can be appropriately determined according to its purpose of use (prevention, health or improved treatment). In general, in the manufacture of food or beverage, the extract of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the raw material. However, in the case of long-term intake for health and hygiene purposes or for health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range. .

There are no particular restrictions on the type of food. Using the mixed fermentation product, it is possible to manufacture processed foods having good storage characteristics while simultaneously transforming the characteristics of agricultural products, livestock products or aquatic products. Such processed foods include, for example, confectionery, fermented foods, canned foods, milk processed foods, meat processed foods, noodles, and the like. Cookies include biscuits, pies, breads, candies, jellies, chewing gum, and cereals (including meal substitutes such as cereal flakes). Fermented foods include soy sauce, miso, and red pepper paste. Canned foods include canned fish (eg, canned tuna, mackerel, saury, turban, etc.), canned livestock products (canned beef, pork, chicken, turkey, etc.), canned agricultural products (canned corn, peach, pineapple, etc.). Milk processed foods include cheese, butter, and yogurt. Meat processed foods include pork cutlet, beef cutlet, chicken cutlet, sausage, sweet and sour pork, nuggets, and bread, and so on. Contains noodles such as sealed packaging noodles. In addition to this, the composition may be used for retort foods, soups, and the like.

In addition, the present invention provides a health functional beverage for preventing or improving liver disease containing a mixture of cheonma and slug.

The health functional beverage composition containing the mixed fermentation product of the present invention may contain various flavoring agents or natural carbohydrates, etc., as additional components, like a conventional beverage. The aforementioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g per 100 ml of the composition of the present invention, preferably about 0.02 to 0.03 g.

In addition to the above, the composition for preventing or improving liver disease of the present invention includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acids and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers , Preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like. In addition, the composition for preventing or improving liver disease of the present invention may contain flesh for the preparation of natural fruit juice, fruit juice beverage and vegetable beverage. These ingredients may be used independently or in combination. The proportion of these additives is not critical, but is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

The present invention also

(1) preparing a sterilized mixture of cheonma powder and slug powder in a 1 to 2: 1 weight ratio; And

(2) After adding water and lactic acid bacteria culture solution to the mixture prepared in the step (1), fermentation method for the improvement of hepatic function, including the step of fermenting for 66-78 hours in an incubator at 36~38°C. to provide.

The method for preparing a mixed fermentation product of Cheonma and slug for improving liver function of the present invention is more preferably

(1) preparing a sterilized mixture of cheonma powder and slug powder in a 1 to 2: 1 weight ratio; And

(2) After adding water and lactic acid bacteria culture solution to the mixture prepared in the step (1), fermentation method for improving liver function, including fermentation for 72 hours in an incubator at 37° C., is provided.

Hereinafter, examples of the present invention will be described in detail. However, the following examples are merely illustrative of the present invention, and the contents of the present invention are not limited to the following examples.

Manufacturing example 1. Mixing thousand horses and slugs Fermentation

(1) Gastrodia elata ) A mixture of powder and slug powder in a 1:1 weight ratio was sterilized for 15 minutes using a high pressure steam sterilizer (121°C and 1.2 atmospheres).

(2) Lactobacillus brevis ( Lactobacillus brevis ), Lactobacillus pertumum ( Lactobacillus fermentum ) and Lactobacillus plantarum ( Lactobacillus plantarum ) were inoculated into three types of lactic acid bacteria in an MRS liquid medium and incubated for 24 hours in an incubator at 37°C. Dilute to a concentration of 10 ⁶ CFU/ml to prepare a culture medium for lactic acid bacteria.

(3) After adding 70 mL of sterile water to 30 g of the sterilized mixture of step (1), inoculate 3 mL of the lactic acid bacteria culture solution prepared in step (2), and incubate for 72 hours in an incubator at 37° C. for millenium and slug. A mixed fermentation product was prepared.

Manufacturing example 2. Cheonma and slug mix Fermentation

In the method of Preparation Example 1, a fermented product of cheonma and slug was prepared, but a mixture of cheonma and slug powder of step (1) in a 2:1 weight ratio was used to prepare a mixture of cheonma and slug.

Manufacturing example 3. Cheonma and slug mix Fermentation Health functional foods used

Cheonma and slug mixed fermentation products prepared by the method of Preparation Example 1, 30 g, wolfberry 30 g, and 60 g of celestial arch are mixed to prepare a health functional food that helps to improve headache and dizziness as well as prevent and improve liver disease. Did.

Manufacturing example 4. Cheonma and slug mix Fermentation Health functional foods used

Cheonma and slug mixed fermentation products prepared by the method of Preparation Example 2 75 g, hyeonggae 15 g, Mok 15 g, gyeji 15 g and 15 g of celestial arch are mixed to prevent and improve liver disease, migraine, cardiovascular disease and Manufactured health functional foods to help improve Boss Hyun-hoon.

Manufacturing example 5. Cheonma and slug mix Fermentation Health functional foods used

Cheonma and slug mixed fermentation products prepared by the method of Preparation Example 2, 10 g, wild chrysanthemum 4 g, wormworm 4 g, wolfberry 4 g, and 5 g of celestial arch are mixed to help improve liver disease and improve hypertension, as well as to prevent and improve liver disease. A health functional food was prepared.

Manufacturing example 6. Mixing thousand and slugs Fermentation Health functional foods used

Cheonma and slug mixed fermentation products prepared by the method of Preparation Example 1 15 g, Baekchul 9 g, Bokryeong 9 g, Dermis 6 g, Licorice 6 g, Ginger 6 g, Seokchangpo 4 g and 3 jujubes are mixed, liver In addition to the disease prevention and improvement effect, a health functional food was prepared to help improve dizziness and memory.

Comparative example 1. Cheonma Fermentation

(1) Cheonma powder was sterilized for 15 minutes using a high-pressure steam sterilizer (121°C and 1.2 atmospheres).

(2) Lactobacillus brevis ( Lactobacillus brevis ), Lactobacillus pertumum ( Lactobacillus fermentum ) and Lactobacillus plantarum ( Lactobacillus plantarum ) were inoculated into three types of lactic acid bacteria in an MRS liquid medium and incubated for 24 hours in an incubator at 37°C. Dilute to a concentration of 10 ⁶ CFU/ml to prepare a culture medium for lactic acid bacteria.

(3) After adding 70 mL of sterile water to 30 g of the sterilized cheonma powder in the step (1), inoculate 3 mL of the lactic acid bacteria culture solution prepared in the step (2) and incubating for 72 hours in an incubator at 37° C. to ferment cheonma Water was prepared.

Comparative example 2. Slugs Fermentation

(1) The slug powder was sterilized for 15 minutes using a high pressure steam sterilizer (121°C and 1.2 atmospheres).

(2) Lactobacillus brevis ( Lactobacillus brevis ), Lactobacillus pertumum ( Lactobacillus fermentum ) and Lactobacillus plantarum ( Lactobacillus plantarum ) were inoculated into three types of lactic acid bacteria in an MRS liquid medium and incubated for 24 hours in an incubator at 37°C. Dilute to a concentration of 10 ⁶ CFU/ml to prepare a culture medium for lactic acid bacteria.

(3) After adding 70 mL of sterile water to 30 g of the sterilized slug powder of the step (1), inoculate 3 mL of the lactic acid bacteria culture solution prepared in the step (2) and incubating for 72 hours in an incubator at 37° C. to ferment the slug. Water was prepared.

Comparative example 3. Cheonma and slug mix Fermentation

A mixed fermentation product was prepared by the method of Preparation Example 1, but the step ( Gastrodia) elata ) A mixed fermentation product was prepared using a mixture of powder and slug powder in a 1:2 weight ratio.

Comparative example 4. yam And slug mix Fermentation

A mixed fermentation product was prepared by the method of Preparation Example 1, but Chunma ( Gastrodia elata ) without using yam ( Dioscorea japonica ) powder to prepare a mixed fermentation.

1. Experimental method

(1) Experimental animals, breeding conditions and dietary composition

Experimental animals were purchased from 5 weeks old Sprague-Dawley-based male rats from Daehan Biolink (Eumseong, Chungbuk). It was used in this experiment after adapting to the environment while feeding commercial solid feed for a week. In this experiment, the body weight was equally classified as a randomized complete block design, and the breeding room temperature (22±2℃), humidity (50±5%) and contrast cycle (light cycle: 07:00~19) in a stainless individual cage. :00) was kept in a controlled animal breeding room. Six were divided into each group, and diet and water were freely consumed for 8 weeks. During the breeding period, dietary intake was measured at regular times every day, and body weight was measured every other day. Animal breeding was in accordance with the National Institutes of Health guidelines for breeding and use of laboratory animals.

(2) Animal experiment, sample collection and analysis sample preparation

The animal experiments were bred for 10 days while feeding the formula for each group, and after fasting for 12 hours or more on the last day of the experiment, they were dissected by light anesthesia with ether. After opening, blood was collected from the abdominal aorta and blood was collected, left at room temperature for about 30 minutes, and then centrifuged at 3,000 rpm for 20 minutes to obtain serum to provide for serum enzyme analysis. After blood collection, each tissue was extracted, washed with cold 0.9% physiological saline, dried with filter paper, weighed, and provided as an analysis sample.

(3) Measurement of blood alcohol and acetaldehyde levels

The concentration of alcohol and acetaldehyde contained in the serum was measured using a commercial UV-Test kit (R-Biopharm). That is, the concentration of alcohol in blood was measured by adding 0.1 ml of serum to a mixture of 3 ml of NAD and phosphate buffer (pH 9.0), reacting for about 3 minutes, measuring absorbance at 340 nm, and adding 0.05 ml of ADH (Alcohol Dehydrogenase) to the mixture. Incubation for 10 minutes at ℃ observed the change in absorbance according to the concentration of NADH generated at 340 nm. At this time, the alcohol concentration (%) in the blood was calculated using a standard solution.

(4) ADH (alcohol dehydrogenase ) And ALDH (Acetaldehyde dehydrogenase ) Enzyme activity measurement

To measure the activity of ADH derived from liver tissue, Bergmeyer's method was slightly modified to measure the rate of NADH production at an absorbance of 340 nm. That is, the composition of the reaction solution was 1.5 ml of distilled water, 0.75 ml of 1M Tris-HCl buffer (pH 8.8), 20 mM NAD+0.3 ml, ethanol 0.3 ml, and 0.15 ml of enzyme source in a cuvette and adjusted to a total of 3 ml at 30°C. After pre-incubation for 5 minutes, the change in absorbance at 340 nm for 5 minutes was measured. For the measurement of ALDH activity derived from liver tissue, the principle of generating NADH from the enzyme NAD producing acetate in acetaldehyde was modified by slightly modifying a method such as Koivula. That is, the composition of the reaction solution is 2.2 ml of distilled water, 0.3 ml of 1M Tris-HCl buffer (pH 8.0), 20mM NAD+0.1 ml, 1M acetaldehyde 0.1 ml, 3M potassium chloride (KCl) 0.1 ml, 0.1 ml of 0.33M 2-mercaptoethanol and 0.1 ml of enzyme source were adjusted to a total of 3 ml, placed in a cuvette, pre-incubated at 30° C. for 5 minutes, and then changed in absorbance at 340 nm for 5 minutes. Was measured.

(5) Statistics processing

The results obtained from the experiments were expressed as mean and standard error (mean±SE) by one-way ANOVA test, and the significance test between each experimental group was done by Duncan's multiple range test.

Example 1. Changes in blood alcohol and acetaldehyde levels

In the present invention, the effect of the mixed fermentation on hangover cancellation and alcohol metabolism was examined, and the blood alcohol concentration was not detected in the blood of the untreated group and alcohol was detected in all the experimental groups to which the alcohol was administered. However, compared to the alcohol group, the alcohol concentration was significantly decreased by the administration of the sample, and among them, the administration group of Production Example 1 decreased the most. The concentration of acetaldehyde in the blood increased significantly in all groups of the alcohol test group compared to the untreated group.

Changes in blood alcohol and acetaldehyde levels according to the administration of fermentation products to alcohol-fed rats division Blood alcohol (%) Blood acetaldehyde (mg/L) No treatment 0.000±0.00 ^a 2.32±0.12 ^a Alcohol benefits 0.051±0.00 ^e 3.68±0.24 ^b Alcohol + Production Example 1 0.030±0.00 ^b 5.93±0.60 ^e Alcohol + Comparative Example 1 0.041±0.00 ^d 4.82±0.42 ^c Alcohol + Comparative Example 2 0.038±0.00 ^c 4.96±0.22 ^c Alcohol + Comparative Example 3 0.036±0.00 ^c 5.02±0.38 ^d Alcohol + Comparative Example 4 0.035±0.00 ^c 5.18±0.40 ^d

Example 2. Liver tissue ADH And ALDH Active change

In this animal experiment, the ADH activity in liver tissue showed a tendency to increase in the alcohol group and the sample administration group compared to the untreated group, of which the sample administration group in Production Example 1 showed the most activity increase. ALDH activity was not different between the normal group and the alcohol control group, but it was shown that the activity was significantly increased by the administration of the sample. These results show that the mixed fermentation product effectively reduces the concentration of alcohol and acetaldehyde in alcohol-treated rats because it promotes the activity of the alcohol metabolizing enzymes ADH and ALDH in liver tissue, and the high acetaldehyde concentration in the previous results is ALDH. It is thought to be degraded by metabolism.

Changes in ADH and ALDH activity of liver tissue following administration of fermentation product to alcohol-fed rats division ADH (nmol NADH/mg protein/min) ALDH (nmol NADH/mg protein/min) No treatment 6.25±0.1 ^a 7.34±0.2 ^a Alcohol benefits 6.38±0.5 ^a 7.60±0.4 ^a Alcohol + Production Example 1 10.30±0.6 ^d 11.03±0.6 ^e Alcohol + Comparative Example 1 7.86±0.1 ^b 8.82±0.2 ^b Alcohol + Comparative Example 2 7.94±0.6 ^b 9.14±0.3 ^b Alcohol + Comparative Example 3 8.82±0.8 ^c 9.92±0.7 ^c Alcohol + Comparative Example 4 9.16±0.9 ^c 10.68±0.4 ^d

Example 3. Blood aspartic acid Aminotransferase ( AST ), Alanine Aminotransferase (ALT), Gamma-glutamyltranspeptidase (γ- GTP ), alkaline phosphatase (ALP) and lactate dehydrogenase ( LDH ) Active change

Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyltranspeptidase (γ-GTP), alkaline phosphatase (ALP), used as clinical indicators of liver damage ) And Lactate Dehydrogenase (LDH) activity measurement, the results of verifying liver function efficacy are shown in Table 3. The activity of serum aspartic acid aminotransferase (AST) and alanine aminotransferase (ALT) is high because the aminotransferase is released into the blood as the necrosis of hepatocytes and the destruction of liver tissue progresses due to liver damage. This is an important clue to the indicator.

In this experiment, the activity of aspartic acid aminotransferase (AST), alanine aminotransferase (ALT), and gamma glutamyltranspeptidase (γ-GTP) was increased in the alcohol-administered group, but aspartic acid aminotransferase (AST) in the alcohol-administered group ), increased activity of alanine aminotransferase (ALT) and gamma glutamyltranspeptidase (γ-GTP) showed a decreased value by sample treatment, and among them, it was found to be significantly decreased in Preparation 1 administration group.

It has been reported that lactic acid dehydrogenase (LDH) and alkaline phosphatase (ALP) activities in the blood, which are used as clinical functional indicators of the liver, have been closely related to the induction of alcoholic liver toxicity due to increased alcohol consumption. In this experiment, lactic acid dehydrogenase (LDH) activity also showed a tendency to increase in the alcohol-administered group, but the increase by the alcohol was significantly decreased by sample administration, of which the lowest value was observed when the sample was administered to the preparation. Therefore, it is judged that the mixed fermentation product of 1 may be used as a health functional food material that can improve alcoholic liver disease.

Changes in blood AST, ALT, γ-GTP, ALP and LDH activity according to the administration of fermentation product to alcohol-fed rats division AST(IU/L) ALT (IU/L) γ-GTP (IU/L) ALP (IU/L) LDH (IU/L) No treatment 122.2±7.8 26.2±2.2 1.32±0.2 700.2±52.2 1425.8 Alcohol benefits 146.5±12.5 43.1±3.2 1.55±0.2 902.8±32.2 2255.6 Alcohol + Production Example 1 69.2±5.6 22.0±1.0 1.12±0.2 752.3±20.4 941.5 Alcohol + Comparative Example 1 100.6±14.2 34.5±0.9 1.43±0.1 860.5±14.8 1721.6 Alcohol + Comparative Example 2 95.6±18.3 33.2±1.4 1.40±0.2 846.8±37.2 1654.2 Alcohol + Comparative Example 3 90.1±10.1 29.8±1.6 1.33±0.1 812.6±42.1 1358.2 Alcohol + Comparative Example 4 82.5±6.8 27.0±1.8 1.20±0.2 795.2±21.4 1225.8

Although the production examples and examples of the present invention are presented above, the present invention is not limited to the above, and various modifications are possible within the technical spirit of the present invention, and such modifications will belong to the claims of the present invention described below.

Claims (6)

delete delete delete delete delete (1) preparing a mixture of cheonma ( Gastrodia elata ) powder and slug powder in a 1:1 weight ratio by sterilizing at 121°C and 1.2 atmospheres for 15 minutes;
(2) Lactobacillus brevis ( Lactobacillus brevis ), Lactobacillus performance ( Lactobacillus fermentum ), and Lactobacillus plantarum ( Lactobacillus plantarum ) were inoculated into three types of lactic acid bacteria in a medium and cultured for 24 hours in a 37° C. incubator 10 ⁶ Preparing a lactic acid bacteria culture solution by diluting to a concentration of CFU/ml; And
(3) After adding 70 mL of sterile water to 30 g of the sterilized mixture prepared in the step (1), inoculating 3 mL of the lactic acid bacteria culture solution prepared in the step (2) and incubating for 72 hours in an incubator at 37°C. A method of manufacturing a fermented mixture of cheonma and slug for improving liver function.